▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #864 by analyst upside · 2026-11-12
CERS
Cerus Corporation
Healthcare · Market Cap $428M · P/E 0x
ANALYST PRICE TARGET
+141.7%
implied upside to consensus target
Current Price $2.12
Consensus Target $5.12
Bull Target $6.5
Bear Target $4.0
Analysts Covering 4
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
4
Hold
0
Sell
0
52-Week Low $1.47
52-Week High $3.47
YTD Return +7.6%
FUNDAMENTALS
Market Cap $428M
P/E Ratio (TTM) N/A
Forward P/E 141.3x
EPS (TTM) $-0.04
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $227M
Profit Margin -3.2%
52-WEEK RANGE
52-Week Low $1.47
52-Week High $3.47
Current Price $2.12
Bear Target $4.0
Bull Target $6.5
● Now $2.12 ● Target $5.12
TRADING DATA
Avg Volume 2.0M
YTD Return +7.6%
Analyst Count 4
Consensus Buy
Upside to Target +141.7%
Last Updated 2026-11-12

ANALYST SUMMARY

Cerus Corporation (CERS) is currently trading at $2.12 with a Wall Street consensus price target of $5.12, implying potential upside of 141.7% over the next 12 months. 4 analysts currently cover CERS, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $6.5, while the most cautious has a target of $4.0.

CERS operates in the Healthcare sector with a market capitalisation of $428M. The stock is up 7.6% year-to-date and is currently trading near the lower end of its 52-week range of $1.47 – $3.47.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

CRMD +190.6%
CorMedix Inc.
$421M · P/E 2.6x · Strong Buy
ASMB +128.9%
Assembly Biosciences, Inc.
$455M · P/E 20.5x · Buy
ALEC +48.3%
Alector, Inc.
$392M · P/E 7.1x · Hold
KMDA +66.1%
Kamada Ltd.
$469M · P/E 21.4x · Buy
ZVRA +113.1%
Zevra Therapeutics, Inc.
$705M · P/E 9.7x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for CERS, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Freedom Broker ● Initiated
Buy 2026-08-20 Building track record
BTIG ↑ Upgrade
Neutral → Buy 2026-05-01 38% win rate (8 calls)
Cantor Fitzgerald reit
Overweight → Overweight 2025-02-21 40% win rate (10 calls)
Stifel - Reiterated
Buy → Buy 2024-10-17 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
45
out of 100
Coverage depth
12/30
Consensus clarity
6/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →